SB 372 - This act enacts provisions relating to payments for prescription drugs. MISSOURI CONSOLIDATED HEALTH CARE PLAN PHARMACY BENEFITS MANAGER (Section 103.200) Before March 1, 2027, and annually thereafter, the pharmacy benefits manager ("PBM") utilized by the Missouri Consolidated Health Care Plan ("the Plan") shall file a report with the Plan for the immediately preceding calendar year. The report shall include certain information regarding the Plan, including the aggregate dollar amount of rebates the PBM collected from pharmaceutical manufacturers, and the aggregate dollar amount of the rebates that were not passed on to the Plan. (Section 103.200.2). The Plan shall establish a form for the reporting, in consultation with its PBM, designed to minimize administrative burden and cost. (Section 103.200.3). Documents, materials, and other information submitted to the Plan under these provisions shall not be subject to disclosure under the Sunshine Law, except to the extent they are reported in the aggregate in the reports submitted to the General Assembly or Director of the Department of Commerce and Insurance under the act. The Plan shall not disclose any information under these provisions in a manner that would compromise the financial, competitive, or proprietary nature of the information, or allow a third party to identify rebate values for a particular outpatient prescription drug or class of outpatient prescription drugs. (Section 103.200.4). The Plan shall also annually report to the General Assembly the aggregate dollar amount of pharmaceutical rebates received for covered drugs utilized by enrollees during the calendar year. (Section 103.200.5(1)). The Plan shall annually produce and provide to the General Assembly and Director of the Department of Commerce and Insurance a report for the immediately preceding calendar year describing the rebate practices of the Plan and its pharmacy benefits manager, as specified in the act. (Section 103.200.5(2)). The Plan may impose a penalty of up to $7,500 on its PBM for each violation of these provisions. (Section 103.200.6). These provisions are identical to provisions in SB 1213 (2024), SB 402 (2023), and HB 197 (2023), and substantially similar to provisions in SB 921 (2022) and HCS/HB 1677 (2022). FREEDOM OF CHOICE FOR PHARMACY SERVICES (Sections 338.015) The act specifies that certain provisions of law pertaining to pharmacists and pharmacies shall not be construed to prohibit patients' ability to obtain prescription services from any licensed pharmacist "or pharmacy", and repeals language specifying that the provisions do not remove patients' ability to waive their freedom of choice under a contract with regard to payment or coverage of prescription expenses. (Section 338.015.1). Under the act, no PBM shall penalize or restrict a covered person from obtaining services from a contracted pharmacy, as such terms are defined by law. (Section 338.015.4). These provisions are substantially similar to provisions in SB 45 (2025), SB 512 (2025), HB 474 (2025), and HCS/HBs 982 & 840 (2025), identical to provisions in SB 1213 (2024), SB 843 (2024), SB 1105 (2024), HB 1627 (2024), and HB 197 (2023), and substantially similar to provisions in SB 921 (2022) and HCS/HB 1677 (2022). PHARMACY BENEFITS MANAGERS (Section 376.387 and 376.388) Additionally, the act modifies the applicable definition of "covered person" for purposes of certain statutes governing PBMs to apply only to individuals who receive prescription drug coverage through a PBM (Section 376.387.1(1)), repeals a provision of law allowing PBMs to hold pharmacists or pharmacies responsible for fees related to charges for administering a health benefit plan (Section 376.387.4), and repeals a provision of law specifying that certain PBM regulations shall not apply with regard to Medicare Part D or other health plans regulated under federal law. (Former section 376.387.5). Pharmacy benefits managers shall notify contracted health carriers in writing of any conflict of interest, any commonality of ownership, or any other relationship between the PBM and any other health carrier with which the PBM contracts. (Section 376.387.5). The act provides standardized definitions for the terms "generic" and "rebate" applicable to PBMs and health carriers (Section 376.387.6-7), and specifies that PBMs shall owe a fiduciary duty to any entity with which it contracts. (Section 376.387.8). The act repeals a portion of a definition to specify that certain provisions relating to the maximum allowable cost of a prescription drug are applicable to all pharmacies, rather than only to contracted pharmacies (Section 376.388.1(1)), and modifies the applicable definition of PBM to refer to any entity that administers or manages a pharmacy benefits plan or program, as defined in the act. (Section 376.388.1(5)). If the reimbursement for a drug to a contracted pharmacy is below the pharmacy's cost to purchase the drug, the PBM shall sustain an appeal and increase reimbursement for the pharmacy and other contracted pharmacies to cover the cost of purchasing the drug. (Section 376.388.5(2)). No PBM shall reimburse a pharmacist or pharmacy in the state an amount less than the amount that the PBM reimburses a PBM affiliate, as defined in the act, for providing the same pharmacist services. (Section 376.388.5(3)). These provisions are similar to provisions in SB 45 (2025), SB 512 (2025), HB 474 (2025), and HCS/HBs 982 & 840 (2025), identical to provisions in SB 1213 (2024), similar to provisions in SB 843 (2024), provisions in SB 1105 (2024), and provisions in HB 1627 (2024), identical to provisions in SB 402 (2023), provisions in HB 197 (2023), substantially similar to provisions in SB 921 (2022), and similar to provisions in HCS/HB 1677 (2022). 340B DRUG PRICING PROGRAM (Section 376.416) No health carrier or PBM shall discriminate against a covered entity or a specified pharmacy, as such terms are defined in the act, by: • Reimbursing a covered entity or specified pharmacy for a quantity of a 340B drug, as defined in the act, in an amount less than the carrier or PBM would pay to any other similarly situated pharmacy for such quantity of the drug on the basis that the entity or pharmacy is a covered entity or specified pharmacy, as defined in the act, or that the entity or pharmacy dispenses 340B drugs (Section 376.416.2(1)); • Imposing any terms or conditions on covered entities or specified pharmacies which differ from the terms or conditions applicable to other similarly situated pharmacies on the basis that the entity or pharmacy is a covered entity or specified pharmacy or dispenses 340B drugs, including but not limited to certain terms and conditions described in the act. (Section 376.416.2(2)); • Interfering with an individual's choice to receive a 340B drug from a covered entity or specified pharmacy. (Section 376.416.2(3)); • Requiring a covered entity or specified pharmacy to identify 340B drugs, either directly or through a third party. (Section 376.416.2(4)); or • Refusing to contract with a covered entity or specified pharmacy for reasons other than those that apply equally to entities or pharmacies that are not covered entities or specified pharmacies, or on the basis that the entity or pharmacy is a covered entity or specified pharmacy, or on the basis that the entity or pharmacy is described as a covered entity under provisions of federal law. (Section 376.416.2(5)). The Director of the Department of Commerce and Insurance shall impose a civil penalty on any PBM violating certain provisions of the act, not to exceed $5,000 per violation per day. (Section 376.416.3). These provisions are similar to provisions in SB 13 (2025), HB 784 (2025), HB 785 (2025), and HB 943 (2025), substantially similar to provisions in SB 1213 (2024), similar to provisions in the truly agreed to and finally passed SS/SB 751 (2024), SCS/SB 978 (2024), SB 1035 (2024), HB 1977 (2024), HCS/HB 2267 (2024) identical to provisions in SB 402 (2023), HB 197 (2023), and similar to provisions in SB 426 (2023), HCS/HB 442 (2023), SB 679 (2023), HB 198 (2023), HB 1330 (2023), SB 921 (2022), HCS/HB 1677 (2022), SB 1129 (2022), and HB 2305 (2022). PHARMACEUTICAL REBATE CERTIFICATION (Section 376.2066) Beginning no later than March 1, 2027, this act requires health carriers to annually certify that they have accounted for rebates, as defined in the act, in calculating health benefit plan premiums. These provisions are identical to provisions in SB 1213 (2024) and similar to provisions in SB 971 (2020). ERIC VANDER WEERD